By Leonid Schneider, on research integrity, biomedical ethics and academic publishing
Paolo Macchiarini affair: I reproduce the letter Patricia Murray, Raphael Levy, Peter Wilmshurst and myself published in The BMJ on 2 March 2022. I also publish Wilmshurst’s appeal to the UCL leadership.
Macchiarini’s victim Paloma Cabeza speaks out again, fearing she doesn’t have much time left. She appeals to the Swedish prosecutor for justice in the deadly trachea transplant scandal.
Veteran journalist Michael Balter is being sued for libel. He appeals to fellow reporters for help.
Swedish academics Nele Brusselaers, Lynn Kamerlin and Pernilla Wittung-Stafshede react to COVID-19 pandemic and ask Swedish authorities: “Yes, it is important to avoid panic – but is it not better to be over-prepared?”
This is the second part of the Bologna whistleblower account. As the university was burying their own misconduct findings, Oxford University Press and their ignoble editor were busy punishing and gaslighting the whistleblower.
Elisabetta Ciani uses mouse models to help children with neurological genetic disorders. Problem is: her own lab members reported Ciani for data manipulation. Records reveal that University of Bologna gaslighted the whistleblower, blamed the transgenic mice alone and fibbed the funding charities.
In this 3rd instalment of her Celixir investigation, Patricia Murray learns whose side the British authority MHRA is on. Not the patients’, and certainly not on the side of facts.
Liverpool professor Patricia Murray continues investigating shady dealings of the regmed company Celixir, owned by struck-off dentist Ajan Reginald and Nobelist Sir Martin Evans
Katrin Amunts is director of Human Brain Project. Back when the Berlin Wall fell, this Moscow-trained young neuroscientist from GDR found a new mentor in Western Germany: Professor Karl Zilles. It is a remarkable story of a literal brain drain.
Patricia Murray uncovers the business secrets of the Nobelist Martin Evans and his partner Ajan Reginald. It seems the magic iMP cells used to treat patients in Greece were drawn from the blood of patients in Swansea, for the purpose of a secret PhD thesis. There is no serious science behind it, only serious investor money and a fraudulent patent.
For Better Science